Amicus Therapeutics (FOLD) Misses Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Amicus Therapeutics Announces Second Quarter 2015 Financial Results and Corporate Updates
August 5, 2015 4:01 PM EDTMarketing Submissions for Galafold® (migalastat HCl) for Fabry Disease Under Review in Europe and on Track for Filing in 2H15 in United States
2Q15 Equity Financing Significantly Strengthens Balance Sheet; More Than $350M Cash on Hand
International Commercial Leadership Team Nearly Complete
Phase 1/2 Clinical Study Initiation of Next-Generation Pompe ERT in 2H15
CRANBURY, N.J., Aug. 5, 2015 (GLOBE NEWSWIRE) --... More
